Health Press Release – Newsletter for March 22, 2011Tuesday, March 22, 2011
Almac and Exco InTouch Form Alliance to Deliver Patient Compliance and ePRO Services Using Multiple Technologies
SOUDERTON, Pennsylvania, March 21, 2011 – The Almac Group and Exco InTouch announced today that Almac's Clinical
Technologies business unit, the leading provider of IXRS(R) (Interactive
Voice and Web Response) services relating to patient and drug supply
management, has formed an exclusive integrated patient management alliance
with Exco InTouch, an innovative firm specializing in patient recruitment,
retention, compliance and …. Original article : Almac and Exco InTouch Form Alliance to Deliver Patient Compliance and ePRO Services Using Multiple Technologies.
Financing Will be Used to Advance the Preclinical Investigation of APIM Therapeutics' Lead Compound in Further Cancer in vivo Studies, Predominantly Myeloma and Acute Myeloid Leukemia
TRONDHEIM, Norway, March 21, 2011 – APIM Therapeutics AS, an early-stage Norwegian therapeutic
company, is pursuing a novel drug approach with the ability to potentiate the
action of a wide range …. Source article on Gaea Times at : APIM Therapeutics Closes a Seed-Follow-Up Financing Round.
FDA Assigns PDUFA Date for Shire’s FIRAZYR(R) (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema
DUBLIN and LEXINGTON, Massachusetts, March 21, 2011 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced that the US Food and Drug
Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA)
date of August 25, 2011 for the review of the New Drug Application (NDA) for
FIRAZYR(R) (icatibant) for the treatment …. Source article on Gaea Times at : FDA Assigns PDUFA Date for Shire's FIRAZYR(R) (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema.
Finesse Launches RemoteView OPC and BatchReport Modules for Intelligent Harmonization of Third Party Bioreactor Controllers and Analyzers with TruBio DV 4.0 Bioprocess Software
SANTA CLARA, California, March 21, 2011 – Finesse Solutions, LLC, a manufacturer of measurement and control
solutions for life science process applications, has announced the official
launch of two new core modules for off-line data processing in its fourth
generation TruBio DV software. These modules are targeted at enabling
bioprocessing specialists to manage data from third party equipment … Original source on Gaea Times at : Finesse Launches RemoteView OPC and BatchReport Modules for Intelligent Harmonization of Third Party Bioreactor Controllers and Analyzers with TruBio DV 4.0 Bioprocess Software.
First Presentations of European-Australian and North American Phase III Trials at European Association of Urology Congress
TOKYO, March 21, 2011 – Astellas Pharma Inc. (www.astellas.com/en/corporate/)
(TSE:4503,"Astellas") today announced the results of two pivotal phase III
clinical trials for mirabegron, the first of a new class of compounds under
development for the treatment of overactive bladder (OAB), show mirabegron
significantly …. Read the original article : Phase III Results Show Mirabegron Improves Key OAB Symptoms.
New Data Published in Nature Genetics Demonstrate That Tiny LNA-Based Compounds Developed by Santaris Pharma A/S Inhibit Entire Disease-Associated microRNA Families
Tiny Locked Nucleic Acid (LNA) based compounds, which are 8-mer LNA oligonucleotides, successfully inhibit entire microRNA families, providing potential new approach for treating a variety of diseases, including cancer, viral infections, cardiovascular and muscle diseases
HOERSHOLM, Denmark and SAN DIEGO, March 21, 2011 – A study published online in this week's Nature Genetics demonstrates that
tiny …. Source : New Data Published in Nature Genetics Demonstrate That Tiny LNA-Based Compounds Developed by Santaris Pharma A/S Inhibit Entire Disease-Associated microRNA Families.
"All developed nations should be on standby for immediate response to limit damage and to aid recovery," advise MENA disaster and emergency response experts
ABU DHABI, UAE, March 21, 2011 – The apocalyptic images coming out of Japan following the recent
earthquake and subsequent tsunami are a bitter reminder of the devastation
wreaked by natural disasters. As …. Original article on Gaea Times at : Emergency Planning Crucial in Disaster Recovery.
LONDON, March 21, 2011 – Buzzbnk, the social venture crowd-funding platform, has today extended
its fund-raising options by launching its first gift vouchers for social
The gift vouchers and certificates – available from GBP5 – offer another
model to fund and support social enterprise, targeting a range of projects
large and small.
…. Source article : A Whole New Way to Give and Participate in Social Good!.
Abbott’s New HIV-1 Qualitative Assay Improves Testing Access in Remote Areas for Children and Adults
WIESBADEN, Germany, March 21, 2011 – Abbott (NYSE: ABT) announced today that it has received CE-Mark for a new
qualitative PCR-based HIV-1 test that produces highly accurate results from
dried blood spot and plasma specimens. The new assay is a long-awaited
diagnostic tool for health officials in African nations and other
resource-limited areas to detect HIV-1 infected infants … Read more >>.
NEW YORK, March 21, 2011 – NeuroFocus unveiled the first dry, wireless headset designed to capture
brainwave activity across the full brain today at the 75th Annual Advertising
Research Foundation conference being held at the Marriott Marquis in New
York. Developed over the last three years, Mynd(TM) combines medical-grade
technology with mobility, leapfrogging current neurological testing methods.
For the … Read more »»».
BIRMINGHAM, England, March 21, 2011 – Personal injury lawyers are anticipating a dramatic rise in workplace
accidents as a result of today's announcement by Work and Pensions Minister,
Chris Grayling MP, that they will cut 11,000 workplace health and safety
Birmingham based Law firm DBS law operate a specialist national personal
injury claims business, … Original article on : Lawyers say Government Health and Safety Plans Put Workers at Risk.
Ongoing Extension Study Results Provide Further Evidence for First-Line Use of FIRMAGON(R) (degarelix) in Advanced Prostate Cancer
For Non-US Media
VIENNA, Austria, March 21, 2011 – Recent data from the ongoing five-year FIRMAGON(R) (degarelix) extension
study (CS21a) has demonstrated the long term efficacy and tolerability of
FIRMAGON(R) in study patients with advanced hormone-dependent prostate cancer
and support its use as first-line androgen deprivation therapy. Full
details were shared today at the European Association of Urology (EAU) …. Source : Ongoing Extension Study Results Provide Further Evidence for First-Line Use of FIRMAGON(R) (degarelix) in Advanced Prostate Cancer.
New Research Unveiled as "Acne Perceptions" Campaign Launched
HARROGATE, England, March 21, 2011 – Shocking results from new research to be unveiled by the Acne Academy
will reveal the extent of the psychological impact of growing up with acne.
With 80% of the UK population suffering from acne at some point in their
lives, this raw and revealing … Read more : Invitation to Acne Academy's Inaugural Press Conference.